Osiris Therapeutics
-
Sports Medicine
Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat…
Read More » -
Financial
Osiris Therapeutics Announces Second Quarter 2015 Financial Results
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions…
Read More » -
Extremities
Stryker Spine and Stryker Trauma and Extremities to Launch Next Generation Viable Bone Matrix at the American Academy of Orthopaedic Surgeons
ALLENDALE, N.J., March 24, 2015 /PRNewswire/ — Stryker Corporation’s Spine and Trauma & Extremities Divisions will be launching BIO4™, the next generation viable bone matrix at…
Read More » -
Hospitals
Osiris Therapeutics to Present at the 3rd Annual Regen Med Investor Day
COLUMBIA, Md., Mar 23, 2015 (BUSINESS WIRE) — Osiris Therapeutics, Inc.OSIR, -0.06% the leading cellular regenerative medicine company focused on developing and marketing…
Read More »